leukocytes

[Clinical Cancer Research] The authors conducted a Phase I trial in 36 patients with hepatocellular carcinoma who were given therapeutic C/EBPα saRNA (MTL-CEBPA) as either neoadjuvant or adjuvant treatment. MTL-CEBPA treatment in those patients caused a marked decrease in peripheral blood monocytic myeloid-derived suppressor cell numbers.

[Scientific Reports] Scientists tested whether selective hematopoietic upstream stimulatory factor 1 (USF1) deficiency could also beneficially impact the development of atherosclerosis. Absence of USF1 function in bone marrow-derived cells was associated with exacerbated blood leukocyte and peritoneal leukocyte lipid loading and an increased atherosclerosis susceptibility.

[Cell Reports] Scientists used genetic engineering to create human PSCs in which the majority of the polymorphic human leukocyte antigens, the main drivers of allogeneic rejection, were deleted.

[Nature Reviews Immunology] The authors review key molecular mechanisms of immune cell activation implicated in modulating atherogenesis and provide an update on the contributions of innate and adaptive immune cell subsets in atherosclerosis.

[Nature Communications] Scientists showed that human T cells engineered to express an mLPA-specific TCR, targeted diverse CD1c-expressing leukemia blasts in vitro and significantly delayed the progression of three models of leukemia xenograft in NSG mice, an effect that was boosted by mLPA-cellular immunization.

[Immunity] Researchers demonstrated that endothelial cells (ECs) of venules in inflamed tissues exhibited a robust autophagic response that was aligned temporally with the peak of neutrophil trafficking and was strictly localized to EC contacts.